Literature DB >> 17588751

Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and X-ray crystallographic studies.

Claudia Temperini1, Alessio Innocenti, Antonio Mastrolorenzo, Andrea Scozzafava, Claudiu T Supuran.   

Abstract

Sulthiame, a clinically used antiepileptic, was investigated for its interaction with 12 catalytically active mammalian carbonic anhydrase (CA, EC 4.2.1.1) isoforms. The drug is a potent inhibitor of CA II, VII, IX, and XII (K(I)s of 6-56 nM), and a medium potency inhibitor against CA IV, VA, VB, and VI (K(I)s of 81-134 nM). The high resolution crystal structure of the hCA II-sulthiame adduct revealed a large number of favorable interactions between the drug and the enzyme which explain its strong low nanomolar affinity for this isoform and may also be exploited for the design of effective inhibitors incorporating sultam moieties.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17588751     DOI: 10.1016/j.bmcl.2007.06.044

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

Review 1.  Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding.

Authors:  Vijay M Krishnamurthy; George K Kaufman; Adam R Urbach; Irina Gitlin; Katherine L Gudiksen; Douglas B Weibel; George M Whitesides
Journal:  Chem Rev       Date:  2008-03       Impact factor: 60.622

Review 2.  Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies.

Authors:  Mateusz Kciuk; Adrianna Gielecińska; Somdutt Mujwar; Mariusz Mojzych; Beata Marciniak; Rafał Drozda; Renata Kontek
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

3.  Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers.

Authors:  Kim Dao; Paul Thoueille; Laurent A Decosterd; Thomas Mercier; Monia Guidi; Carine Bardinet; Sébastien Lebon; Eva Choong; Arnaud Castang; Catherine Guittet; Luc-André Granier; Thierry Buclin
Journal:  Pharmacol Res Perspect       Date:  2020-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.